Wednesday, October 6, 2010

Surviving For Mesothelioma Cancer

 The cancer is rarely found in the United States, with less than 5000 victimized people. Generally, the older generation has been found to be the most affected.

Types of Treatment Available Surgery is the first treatment that the majority of patients go through. The malignant tumor masses are easily removed during surgery. A rather dangerous treatment, sends drugs throughout the body to further reach the cancer areas. Another treatment is using radiation; x-rays in high form. Radiation kills the mesothelioma cells.

Treatment by Chemical is given as a pill to injected into a vein. It can also be injected into the muscle. It is primarily used to target the local area of the tumor. During treatment, patients experience extreme side effects: vomiting, hair loss, nausea, exhaustion, and anorexia. Side effects are harbored specifically with treatments.

Chemotherapy can use a one-pill treatment that has success. Patients have better experiences with this type, also referred to single-agent therapy. Specific agents used are as follows: doxorubicin, carboplatin, mitomucin, cyclophosphamide, Ifosdomide and cisplatin. The response rate to these drugs range depending upon the drug.

A list of the rates follows below along with the related drug:

15% response- doxorubicin, detrorubucin, pirarubicin, and epirubicin. 10%-20%- carboplatin, mitomucin, cyclophosphamide, Ifosdomide and cisplatin. 14% -- listed again is cisplatin. 36%-- cisplatin, a rare case that lasted two to eight months.
The response rates are proven to be extremely low when using single-agent chemotherapy. Scientists are driven to study a number of treatment combinations for mesothelioma cancer patients. They have increased the response rates up to 44%, but still lack effectiveness. The combination treatments are not being used often enough for dramatic changes, slimming the effects on patients to single-agent therapy. A newer combination showing a 47% response rate uses a more recent agent called gemcitabine. The agent is used in combination with cisplatin. This research was performed in Australia by Australian researchers and has proven survival results with Stage III and IV patients. The research ran for 25 weeks and given a chance for survival at 41%.

Given all the regimes for treating people, new research brings more treatments and the tools needed to perform. Doctors are getting many more patients and better at predicting the appropriate regime for specific patients. Patients are diagnosed based on their age and the cancer stage of mesothelioma they are in.

No comments:

Post a Comment